These hybrid mutations occur in approximately 4% of anaplastic thyroid carcinomas (ATCs) and 9% of poorly differentiated thyroid cancers, resulting in sustained activation of the MAPK pathway through MEK signaling [17]. Here, MAP2K7 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.